Temasek Invests in Yichang Hec Changjiang Pharmaceutical

Singapore’s Temasek Holdings has invested in a Chinese pharmaceutical company that manufactures an anti-flu product, among other drugs. Through a series of subsidiaries, Bartley Investments Pte. Ltd., a sovereign wealth enterprise (SWE) of Temasek Holdings, purchased 15.1 million H shares in Yichang Hec Changjiang Pharmaceutical Company Limited. This transaction was recorded on April 27, 2017. The average price per share was HK$ 16.30.

Yichang Hec Changjiang Pharmaceutical was formed in August 2001. The company focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases. According to the company, Kewei (oseltamivir phosphate) is the #1 selling influenza drug in China from 2013 to 2016.

TaiGen Deal

On March 27, 2017, Taiwan-based TaiGen Biopharmaceuticals Co. (Beijing), Ltd., a unit of TaiGen Biotechnology, sold its 9% equity stake in Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. to Yichang Hec Changjiang Pharmaceutical. Dongguan HEC TaiGen Biopharmaceuticals is a joint venture between Yichang Hec Changjiang Pharmaceutical and TaiGen Biopharmaceuticals Co. (Beijing), Ltd.

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates